Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 240 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: aripiprazole (Abilify) Clear all

Conditions: Bipolar Disorder
Interventions: Lamotrigine + Aripiprazole, Lamotrigine + Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 62
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 55 more

Conditions: Schizophrenia
Interventions: LY2140023, Aripiprazole; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Garden Grove, California • Glendale, California

Conditions: Schizophrenia
Interventions: Paliperidone extended release (ER), Aripiprazole; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Dothan, Alabama • Santa Ana, California • Atlanta, Georgia + 3 more

Conditions: Asperger's Disorder, Pervasive Developmental Disorder
Interventions: aripiprazole; Drug
Lead sponsor: Indiana University; Other
Eligibility: 4 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Schizophrenia
Interventions: Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 17
States / cities: Dothan, Alabama • Anaheim, California • Culver City, California + 14 more

Conditions: Obesity, Weight Gain, Psychotropic Induced Weight Gain
Interventions: Metformin; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 10 Years to 17 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Psychiatry
Interventions: Not listed
Lead sponsor: Creighton University; Other
Eligibility: 11 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Schizophrenia
Interventions: Aripiprazole tablet, 10 mg, Aripiprazole tablet, 30 mg, Placebo tablet; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 53
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 50 more

Conditions: Schizophrenia
Interventions: Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc); Drug
Lead sponsor: Matt Byerly; Other
Eligibility: 18 Years to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia, Schizoaffective Disorder, Social Anxiety Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Weight, Body
Interventions: Risperidone, Aripiprazole; Drug
Lead sponsor: Duke University; Other
Eligibility: 3 Years to 18 Years
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 37
States / cities: Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more

Conditions: Depression
Interventions: Drug Abilify; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Bipolar I Disorder
Interventions: aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 13
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Chula Vista, California + 10 more

Conditions: Schizophrenia
Interventions: LY2140023, Placebo, Standard of Care; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more

Conditions: Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Disorders
Interventions: Not listed
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Garden Grove, California • Atlanta, Georgia • Decatur, Georgia + 2 more

Conditions: Schizophrenia OCD, Obsessive Compulsive Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: Jamaica Hospital Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Jamaica, New York

Conditions: Bipolar I Disorder
Interventions: Intramuscular (IM) Depot Aripiprazole, Intramuscular (IM) Depot Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 42
States / cities: Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 39 more

Conditions: Overweight, Hyperlipidemia, Cardiovascular Diseases
Interventions: Aripiprazole; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Schizophrenia, Insulin Resistance
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Generalized Anxiety Disorder, Panic Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Trichotillomania
Interventions: aripiprazole; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pervasive Developmental Disorder
Interventions: Aripiprazole oral product, Placebo oral capsule; Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Schizophrenia Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions: Plasma NDE miRNA Sequencing, Whole Genome Sequencing; Diagnostic Test · Genetic
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 40 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Schizophrenia
Interventions: Aripiprazole Lauroxil; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 18
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 14 more

Search by objective public record fields.

A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode

A Study of Safety and Tolerability in Subjects With Schizophrenia

An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia

A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents

Aripiprazole in Adolescents With Schizophrenia

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

Long-term Antipsychotic Pediatric Safety Trial

Aripiprazole as Augmentation for TRD

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia

Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia

Aripiprazole for the Treatment of Refractory Anxiety

Trial of Aripiprazole in Trichotillomania

Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders

MicroRNAs as Biomarkers in First Episode Schizophrenia

A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia